THE WOODLANDS, Texas, Aug. 12 /PRNewswire/ -- Medical oncologist and renowned cancer researcher Nicholas J. Vogelzang, M.D. has joined the US Oncology Research network and will treat patients at Comprehensive Cancer Centers of Nevada (CCCN), an affiliate of US Oncology, Inc.
Dr. Vogelzang will serve as Chair and Medical Director of the Developmental Therapeutics Committee for US Oncology Research and Co-Chair of the Genitourinary Committee. The US Oncology Research network has a long history of success in cancer research, helping to bring 36 new cancer therapies to market.
"We're honored to add Dr. Vogelzang to the long line of prestigious cancer researchers working in the US Oncology Research network," says Steve Smith, vice president of US Oncology Research. "His talents will allow us to assess clinical trials in a variety of cancers rarely seen in the network in prior years."
"US Oncology Research has developed a strong reputation for doing excellent clinical research on a national level. The addition of Dr. Vogelzang, who is well known for his work in GU malignancies and drug development only strengthens our ability to perform at a very high level," says Stephen Jones, M.D., medical director of the US Oncology Research network, "We are excited about him joining the network."
Dr. Vogelzang's research has been instrumental in developing novel treatments for genitourinary malignancies, including prostate, kidney, bladder, and testicular cancer, and for mesothelioma.
Prior to joining the US Oncology Research network and CCCN, Dr. Vogelzang served as a faculty member at the University of Chicago and later as the director of the University of Chicago Cancer Research Center. In 2004, he joined the Nevada Cancer Institute as its director.
"Many arms make light work," says Dr. Vogelzang. "The US Oncology Research network provides many arms and eager hands to make the research system readily available to multiple patients across the country. Joining the network provides three great opportunities: greater access to clinical trials, a greater opportunity for translational research and a greater opportunity for inclusiveness of all oncology medical fields into the research, including surgeons, medical oncologists, hematologists and radiation oncologists."
US Oncology Research currently has more than 70 open clinical trials in more than 80 sites across 200 locations. US Oncology Research can be accessed by community-based oncology practices in a variety of ways, including access through its electronic health record system, iKnowMed, which is available to oncologists inside and outside of the US Oncology network of physicians. For more information, visit www.usoncology.com.
About US Oncology Research
With experienced investigators and dedicated research nurses, US Oncology Research represents the largest research network specializing in Phase I-IV oncology clinical trials in the United States. US Oncology Research serves more than 80 sites in 200 locations with over 70 open trials being managed at any given time.
Additionally, the research network has accrued over 38,500 patients since its inception and contributed to the development of 36 of the latest cancer-fighting drugs approved by the FDA. For more information, visit the US Oncology Research section under About US Oncology on the company's Web site, www.usoncology.com.
About US Oncology
US Oncology, Inc., headquartered in The Woodlands, Texas, works closely with physicians, payers, biotechnology, pharmaceutical and medical equipment manufacturers, to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation's foremost cancer treatment and research networks, accelerating the availability and use of evidence-based medicine and shared best practices.
US Oncology uses its expertise to support every aspect of the cancer care delivery system--from drug development to distribution and outcomes measurement--enabling the company to help increase the efficiency and safety of cancer care. According to the company's last quarterly earnings report, US Oncology is affiliated with 1,236 physicians operating in 476 locations, including 94 radiation oncology facilities in 39 states. For more information, visit the company's Web site, www.usoncology.com.
About Comprehensive Cancer Centers of Nevada
Comprehensive Cancer Centers of Nevada is the award-winning group of medical, pediatric and radiation oncologists in the state with eight cancer centers throughout the greater Las Vegas Valley. The radiation oncology services offered by the group are accredited by the American College of Radiology. With a specialized physician and nursing staff, Comprehensive Cancer Centers of Nevada offers sophisticated diagnostic tools, the latest advances in cancer treatment, a full range of innovative, exclusive services and research-based care in a supportive and caring environment. Physicians are board-certified in the fields of medical oncology, hematology, pediatric oncology and radiation oncology. The group is comprised of 19 medical oncologists, five radiation oncologists and two pediatric oncologists. Comprehensive Cancer Centers of Nevada is United in Healing with US Oncology. With more than 1,227 physicians treating more than 650,000 patients at 468 locations in 39 states, the US Oncology network and CCCN provide patients with access to the latest advancements in therapies, clinical research and technology, as well as best-in-class clinical and operational processes that help to advance the quality, safety and cost effectiveness of cancer care. The group is also affiliated with the University of California Los Angeles (UCLA), which allows patients to participate in clinical trials developed by UCLA faculty while remaining in Southern Nevada. For more information, visit the company's Web site at www.cccnevada.com.
|SOURCE US Oncology, Inc.|
Copyright©2009 PR Newswire.
All rights reserved